[{"indications": "Indications\u00a0rhinorrhoea associated with allergic and non-allergic\r\nrhinitis", "name": "IPRATROPIUM BROMIDE - ANTIMUSCARINIC", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.2 Drugs acting on the nose", "12.2.2 Topical nasal decongestants", "Antimuscarinic"], "cautions": "Cautions\u00a0see section 3.1.2; avoid\r\nspraying near eyes", "side-effects": "Side-effects\u00a0epistaxis, nasal dryness, and irritation; less\r\nfrequently nausea, headache, and pharyngitis; very rarely antimuscarinic effects such as gastro-intestinal motility disturbances,\r\npalpitations, and urinary retention", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5668.htm", "doses": ["adult and child over 12 years, 42\u00a0micrograms (2 sprays) into\r\neach nostril 2\u20133 times daily"]}, {"indications": "Indications\u00a0reversible airways obstruction, particularly\r\nin chronic obstructive pulmonary disease; rhinitis (section 12.2.2)", "name": "IPRATROPIUM BROMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.1 Bronchodilators", "3.1.2 Antimuscarinic bronchodilators"], "cautions": "Cautions\u00a0\n(From 3.1.2 Antimuscarinic bronchodilators: British National Formulary)\nCautions\u00a0Antimuscarinic bronchodilators should be used with caution in patients with prostatic hyperplasia, bladder outflow obstruction, and those susceptible to angle-closure glaucoma (see below); interactions: Appendix 1 (antimuscarinics).Glaucoma\u00a0Acute angle-closure glaucoma has been reported with nebulised ipratropium, particularly when given with nebulised salbutamol (and possibly other beta2 agonists); care needed to protect patient\u2019s eyes from nebulised drug or from drug powder.", "side-effects": "Side-effects\u00a0\n(From 3.1.2 Antimuscarinic bronchodilators: British National Formulary)\nSide-effects\u00a0Dry mouth is the most common side-effect of antimuscarinic bronchodilators; also constipation, cough, paradoxical bronchospasm, headache, dizziness; less commonly nausea, tachycardia, palpitation, atrial fibrillation, urinary retention, eye pain, corneal oedema, angle-closure glaucoma, blurred vision, stomatitis, rash, and pruritus can occur. Raised intra-ocular pressure and urticaria have occurred rarely.; also\r\nthroat irritation; less commonly vomiting, diarrhoea,\r\nlaryngospasm, pharyngeal oedema, conjunctival hyperaemia, mydriasis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2925.htm", "doses": ["By aerosol inhalation, 20\u201340\u00a0micrograms\r\n3\u20134 times daily; child up to 6 years\r\n20\u00a0micrograms 3 times daily, 6\u201312 years 20\u201340\u00a0micrograms 3 times daily", "By inhalation of powder, adult and child over\r\n12 years, 40\u00a0micrograms 3\u20134 times daily (may be doubled in less responsive\r\npatients)", "By inhalation of nebulised solution, reversible airways obstruction in chronic obstructive pulmonary\r\ndisease, 250\u2013500\u00a0micrograms 3\u20134 times daily", "Acute bronchospasm (but see also Management of Acute Asthma\r\ntable),\r\n500\u00a0micrograms repeated as necessary; child under 5 years 125\u2013250\u00a0micrograms, max. 1\u00a0mg daily; 6\u201312 years 250\u00a0micrograms,\r\nmax. 1\u00a0mg daily", "Advise patient not\r\nto exceed prescribed dose and to follow manufacturer\u2019s directions"], "pregnancy": "Pregnancy\u00a0see section 3.1"}, {"indications": "Indications\u00a0reversible airways obstruction, particularly\r\nin chronic obstructive pulmonary disease; rhinitis (section 12.2.2)", "name": "IPRATROPIUM BROMIDE - ANTIMUSCARINIC BRONCHODILATORS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.1 Bronchodilators", "3.1.2 Antimuscarinic bronchodilators"], "cautions": "Cautions\u00a0\n(From 3.1.2 Antimuscarinic bronchodilators: British National Formulary)\nCautions\u00a0Antimuscarinic bronchodilators should be used with caution in patients with prostatic hyperplasia, bladder outflow obstruction, and those susceptible to angle-closure glaucoma (see below); interactions: Appendix 1 (antimuscarinics).Glaucoma\u00a0Acute angle-closure glaucoma has been reported with nebulised ipratropium, particularly when given with nebulised salbutamol (and possibly other beta2 agonists); care needed to protect patient\u2019s eyes from nebulised drug or from drug powder.", "side-effects": "Side-effects\u00a0\n(From 3.1.2 Antimuscarinic bronchodilators: British National Formulary)\nSide-effects\u00a0Dry mouth is the most common side-effect of antimuscarinic bronchodilators; also constipation, cough, paradoxical bronchospasm, headache, dizziness; less commonly nausea, tachycardia, palpitation, atrial fibrillation, urinary retention, eye pain, corneal oedema, angle-closure glaucoma, blurred vision, stomatitis, rash, and pruritus can occur. Raised intra-ocular pressure and urticaria have occurred rarely.; also\r\nthroat irritation; less commonly vomiting, diarrhoea,\r\nlaryngospasm, pharyngeal oedema, conjunctival hyperaemia, mydriasis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2925.htm", "doses": ["By aerosol inhalation, 20\u201340\u00a0micrograms\r\n3\u20134 times daily; child up to 6 years\r\n20\u00a0micrograms 3 times daily, 6\u201312 years 20\u201340\u00a0micrograms 3 times daily", "By inhalation of powder, adult and child over\r\n12 years, 40\u00a0micrograms 3\u20134 times daily (may be doubled in less responsive\r\npatients)", "By inhalation of nebulised solution, reversible airways obstruction in chronic obstructive pulmonary\r\ndisease, 250\u2013500\u00a0micrograms 3\u20134 times daily", "Acute bronchospasm (but see also Management of Acute Asthma\r\ntable),\r\n500\u00a0micrograms repeated as necessary; child under 5 years 125\u2013250\u00a0micrograms, max. 1\u00a0mg daily; 6\u201312 years 250\u00a0micrograms,\r\nmax. 1\u00a0mg daily", "Advise patient not\r\nto exceed prescribed dose and to follow manufacturer\u2019s directions"], "pregnancy": "Pregnancy\u00a0see section 3.1"}]